Assembly Biosciences Inc — Quarterly Financial Statistics (NASDAQ:ASMB) | MetaTrader

Open full chart

Financials

Overview Finanzbericht Statistics Dividends

Quarterly Annual

Cash from operating activities 15.24 M407 K23.44 M16.76 M15.13 M 55.74 M Cash from investing activities 24.49 M-6.7 M6.59 M16.99 M111.11 M 128 M Cash from financing activities 017 M1.92 M357 K171.93 M 191.21 M Free cash flow 15.24 M407 K23.44 M16.76 M15.09 M 55.7 M

Nachrichten

Personalis (PSNL) Reports Q4 Loss, Misses Revenue Estimates

Supernus Pharmaceuticals (SUPN) Surpasses Q4 Earnings and Revenue Estimates

GILD Exercises Option to License Assembly Bio's Herpes Programs

Gilead Sciences Bets On Weekly Pill To Tackle Genital Herpes - Assembly Biosciences (NASDAQ:ASMB), Gilead Sciences (NASDAQ:GILD)

Gilead exercises option for Assembly Bio’s herpes treatment programs

Assembly Biosciences: Jefferies hebt Kursziel nach positiven HSV-Daten deutlich an

Jefferies raises Assembly Biosciences stock price target to $62 on HSV data

Assembly Biosciences, Inc. (ASMB) Discusses Positive Interim Results for ABI-1179 and ABI-5366 in Recurrent Genital Herpes Phase 1b Studies Transcript

Assembly Biosciences, Inc. (ASMB) Discusses Positive Interim Results for ABI-1179 and ABI-5366 in Recurrent Genital Herpes Phase 1b Studies - Slideshow (NASDAQ:ASMB) 2025-12-08

Assembly Biosciences: Aktie steigt nach vielversprechenden Studienergebnissen zu Herpes-Medikament

Assembly Biosciences stock rises after promising HSV drug results

Assembly Bio meldet starke Studienergebnisse für Herpes-Therapien